Source: Investing.com ↗

Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

BTC/USDT

$65,752.84

-4.62%

USDC/USDT

$1.00

-0.01%

ETH/USDT

$1,834.97

-5.49%

SOL/USDT

$72.45

-9.54%

ZEC/USDT

$848.99

-10.31%